Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services



Gallus BioPharmaceuticals, a St. Louis-based CMO has acquired Laureate Biopharmaceutical Services, a biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development and clinical drug-substance-manufacturing capacity and adds full protein characterization, testing, and clinical fill-finish capability. With the acquisition, Gallus has two centers of excellence. The Princeton site is a Center of Excellence for process development and manufacture of clinical-stage products, including fill-finish, and the St. Louis site is a Center of Excellence for process development and clinical and commercial manufacture of biopharmaceutical products.

Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.

Source: Gallus BioPharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here